This phase III trial aimed to confirm the superiority of weekly docetaxel and cisplatin over docetaxel monotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC).
READ FULL ARTICLE
From Mdlinx
Weekly Docetaxel Plus Cisplatin Not Superior to Docetaxel Monotherapy in Elderly Lung Cancer
the Cancer Therapy Advisor take:
According to a new study published in the Journal of Clinical Oncology, researchers have found that weekly docetaxel plus cisplatin is not superior to docetaxel monotherapy as first-line chemotherapy for elderly patients with advanced non-small cell lung cancer (NSCLC).
For the study, researchers sought to prove that weekly docetaxel and cisplatin demonstrates a survival advantage over docetaxel monotherapy in elderly patients with advanced NSCLC. Researchers enrolled 276 chemotherapy-naive patients with stage III, IV, or recurrent NSCLC (median age 76 years) who were not eligible to receive bolus cisplatin.
Patients were randomly assigned to receive docetaxel 20mg/m2 plus cisplatin 25mg/m2 on days 1, 8, and 15, every 4 weeks, or docetaxel 60mg/m2 on day 1, every 3 weeks. Results showed the median survival times were 13.3 and 14.8 months for the doublet and monotherapy arms, respectively (HR = 1.18; 95% CI: 0.83 - 1.69).
The study was terminated early because an interim analysis demonstrated a predictive probability of 0.996% that the doublet arm would be statistically superior to the monotherapy arm on final analysis.
In regard to safety, grade 3 or higher neutropenia and febrile neutropenia were more common in the monotherapy arm, while anorexia and hyponatremia were more common in the doublet arm.
